Oruka Therapeutics, Inc.
ORKA
$14.51
-$0.925-5.99%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -17.02% | 37.11% | -16.66% | -28.68% | -214.30% |
| Total Depreciation and Amortization | 18.75% | -13.51% | 68.18% | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 17.50% | -26.18% | -59.49% | 1,427.87% | 701.16% |
| Change in Net Operating Assets | 24.56% | -160.27% | 151.72% | -192.51% | 54.20% |
| Cash from Operations | -10.91% | 13.32% | 13.45% | -152.13% | -6,467.26% |
| Capital Expenditure | -161.54% | 63.07% | 79.42% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -88.59% | 111.91% | -- | -- | -- |
| Cash from Investing | -88.66% | 111.91% | -210,407.31% | -- | -- |
| Total Debt Issued | -- | -- | -199.46% | -- | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -100.00% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -93.12% | 510.89% | -- |
| Cash from Financing | -- | -- | -90.48% | 26,767.28% | -105.69% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -182.63% | 106.40% | -186.85% | 3,235.43% | -145.50% |